BioSpace News Archive

MAA is for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and follicular lymphoma grade 3B

$400M Debt Facility Provides Path to Profitability Without the Need for Any Future Dilutive Financings Self-sustainable Financial Profile Achieved with Comprehensive, Low Cost Debt Structure and Includes Retiring Prior Term Loan Company Reiterates 2020 Galafold Revenue of $250-$260M and 2020 Operating Expense Guidance CRANBURY, N.J., July 17, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, develop

First data to read out from the Janssen and MeiraGTx collaboration Johnson & Johnson to review interim Phase 1/2 clinical trial findings in pre-recorded webcast Company anticipates progressing the program to Phase 3

Ocular Therapeutix Presents at the 12 th Annual Ophthalmology Innovation Summit (OIS) DEXTENZA® Sets Billable Insert In-Market Sales Record in June and Company Announces Preliminary Second Quarter 2020 Net Product Revenue BEDFORD, Mass.--( BUSINESS WIRE )-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the e

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the B. Riley FBR Virtual Summer Series panel on antiviral therapeutics on Tuesday, July 21, 2020. Presentation Information: Panel: Antiviral Th

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2020 will be released before market open on Monday, August 3, 2020.

Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced two presentations featuring its Bladder EpiCheck® technology at the 35 th Annual European Association of Urology (EAU) Virtual Congress. The first presentation, titled “Feasibility of the EpiCheck test in upper tract tumor: interim analysis of a prospective trial,” evaluated 47 patie

Ministers and Government of Canada officials will hold a news conference to provide an update on coronavirus disease (COVID-19). Date July 17, 2020 Time 1:00 PM (EDT) Location West Block, Room 225 Parliament Hill Wellington Street, Ottawa, Ontario The media availability will also be held by teleconference. Toll-free

Teligent, Inc. (Nasdaq: TLGT) (“Teligent” or the “Company”), a New Jersey based specialty generic pharmaceutical company, today announced the hiring of Philip Yachmetz as Chief Legal Officer and Corporate Secretary of the Company, effective July 16, 2020. Timothy B. Sawyer, President and CEO of the Company, commented, “We are pleased that Phil has agreed to join our Teligent team. Phil’s extensive experience as a general counsel/chief legal and

International Foundation for Gastrointestinal Disorders raises awareness for Gastroparesis Awareness Month to shed light on the symptom burdens of those living with gastroparesis